144725 20260217205528.0 doi 10.1080/2162402X.2024.2379062 sideral 139541 ART-2024-139541 eng Pesini, Cecilia In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors 2024 Access copy available to the general public Unrestricted Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability. info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00 info:eu-repo/grantAgreement/ES/AEI/RYC2022-036627-I info:eu-repo/grantAgreement/ES/DGA/B29-23R info:eu-repo/grantAgreement/ES/ISCIII/CB21-13-00087 info:eu-repo/grantAgreement/ES/MICINN/PID2022-136554OA-I00 info:eu-repo/semantics/openAccess by-nc https://creativecommons.org/licenses/by-nc/4.0/deed.es 6.3 2024 ONCOLOGY 51 / 328 = 0.155 2024 Q1 T1 IMMUNOLOGY 33 / 183 = 0.18 2024 Q1 T1 2.542 2024 Immunology 2024 Q1 Oncology 2024 Q1 Immunology and Allergy 2024 Q1 12.9 2024 info:eu-repo/semantics/review info:eu-repo/semantics/publishedVersion Artal, Laura Paúl Bernal, Jorge Sánchez Martinez, Diego Pardo, Julián Universidad de Zaragoza (orcid)0000-0003-0154-0730 Ramírez-Labrada, Ariel (orcid)0000-0002-3888-7036 1011 566 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Inmunología 13, 1 (2024), [22 pp.] Oncoimmunology OncoImmunology 2162-4011 3178849 http://zaguan.unizar.es/record/144725/files/texto_completo.pdf Versión publicada 3363920 http://zaguan.unizar.es/record/144725/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:144725 articulos driver 2026-02-17-20:31:21 ARTICLE